Intensity-modulated radiation therapy for prostate cancer: Late morbidity and results on biochemical control

详细信息    查看全文

• 作者：Gert O. De Meerleer ; Valé ; rie H. Fonteyne ; Luc Vakaet ; Geert M. Villeirs ; Ludwig Denoyette ; Antony Verbaeys ; Nicolas Lummen ; Wilfried J. De Neve
• 关键词：Prostate cancer ; IMRT ; Morbidity ; Biochemical control
• 刊名：Radiotherapy and Oncology
• 出版年：2007
• 出版时间：February 2007
• 年：2007
• 卷：82
• 期：2
• 页码：160-166
• 全文大小：111 K

文摘

>Purpose

To report on late morbidity and biochemical relapse-free survival (bRFS) after intensity-modulated radiation therapy (IMRT) for prostate cancer.

Methods

Between 1998 and 2005 133 patients were treated with IMRT for T(1-4) N0 M0 prostate cancer. The median follow-up time was 36 months. In a first cohort, patients received a median planning target volume (PTV) dose of 74 Gy with a hard constraint on maximum rectum dose of 72 Gy (74R72, n = 51). Later, median PTV and maximum rectum dose were increased to 76 and 74 Gy, respectively (76R74; n = 82). We defined low-risk (n = 20), intermediate-risk (n = 70) and high-risk (n = 43) groups. Androgen deprivation was given to patients in the intermediate- and high-risk group. Late gastro-intestinal (GI) and genito-urinary (GU) morbidity and biochemical relapse, in accordance with the ASTRO consensus, were recorded.

Results

We observed grade 2 GI (17 % ) and GU (19 % ), grade 3 GI (1 % ) and GU (3 % ) late toxicities. Except for hematuria, the median duration of side-effects was 6 months. Biochemical relapse-free survival (bRFS) at 3 and 5 years was 88 % and 83 % , respectively, with a significantly better 3-year bRSF for the 76R74 than for the 74R72 group (p = 0.01). Five-year bRFS for patients in the low-risk, intermediate-risk and high-risk group was 100 % , 94 % and 74 % , respectively (p < 0.01).

Conclusion

IMRT for localized or locally advanced prostate cancer combines low morbidity with excellent biochemical control.